Nuns should take contraceptive pill to cut cancer risk
While writing in the Lancet medical journal two health experts have claimed nuns should take the contraceptive pill to reduce their risk of developing cancer.
It is commonly believed that women who do not go through pregnancy or breastfeed children are more at risk of developing breast, womb and ovarian cancer as they have more periods in their lifetime.
Studies of nuns have also found that cancer-related mortality rates are higher among nuns than other women.
To read the latest edition of Healthcare Global, click here
- Cocaine use increasing and drug is on 11 % of banknotes
- Sperm quality could be damaged by using wifi on laptops
- Norovirus present in three quarters of UK-grown oysters
According to the two Australian researchers, overall mortality rates are 12 percent lower in pill-takers and the risk of breast, ovarian and womb cancer is cut by approximately 50-60 percent if women take the pill.
However, nuns have been banned from taking any kind of contraception apart from abstinence.
Professor Roger Short, from the University of Melbourne, and Dr Kara Britt, from Melbourne’s Monash University, said in their Lancet opinion article that nuns “pay a terrible price for their chastity because they have a greatly increased risk of breast, ovarian, and uterine cancers.
They also said: “The Catholic church condemns all forms of contraception except abstinence, as outlined by Pope Paul VI in Humanae Vitae in 1968.
“If the Catholic Church could make the contraceptive pill freely available to all its nuns, it would reduce the risk of those accursed pests, cancer of the ovary and uterus, and give nuns’ plight the recognition it deserves.”
Our magazine is now available on the iPad. Click here to download it.
- HPV Vaccine 'Protects Males from Cancers' - Global ReportMedical Devices & Pharma
- Hologic: How Can Technology be Harnessed to Combat Cancer?Technology & AI
- Asian cancer survivors break stigma in their communitiesSustainability
- Novartis breast cancer drug trial achieves positive resultsMedical Devices & Pharma